65515-28-8

Basic information

• Product Name: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&
• Synonyms: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&;methyl 2,6-dichloronicotinate (en);2,6-two chloroMethyl nicotinate;Methyl2,6-dichloronicotinate,97%;2,6-Dichloropyridine-3-carboxylic acid methyl ester;Methyl 2,6-dichloropyridin-3-carboxylate;3-Pyridinecarboxylic acid, 2,6-dichloro-, methyl ester
• CAS NO: 65515-28-8
• Molecular Formula: C₇H₅Cl₂NO₂
• Molecular Weight: 206.027
• Mol File: 65515-28-8.mol
• Article Data: 33

Chemical Properties

• Melting Point: 56-60 °C(lit.)
• Boiling Point: 270.517 °C at 760 mmHg
• Flash Point: 117.405 °C
• Appearance: /
• Density: 1.426 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.548
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -4.55±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&(65515-28-8)
• EPA Substance Registry System: METHYL 2 6-DICHLOROPYRIDINE-3-CARBOXYLA&(65515-28-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 65515-28-8(Hazardous Substances Data)

Usage

Description

METHYL 2,6-DICHLOROPYRIDINE-3-CARBOXYLA& is an organic compound that serves as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is characterized by its chlorinated pyridine ring and carboxylate group, which can be further functionalized to produce a range of derivatives with diverse applications.

Uses

Used in Pharmaceutical Industry:
METHYL 2,6-DICHLOROPYRIDINE-3-CARBOXYLA& is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its chlorinated pyridine ring and carboxylate group can be modified to produce a range of active pharmaceutical ingredients with different therapeutic properties.
Used in Agrochemical Industry:
METHYL 2,6-DICHLOROPYRIDINE-3-CARBOXYLA& is also used as a building block in the development of agrochemicals, such as herbicides and insecticides. Its unique chemical structure allows for the creation of compounds with targeted pest control properties, contributing to more effective and environmentally friendly agricultural practices.
Used in Organic Synthesis:
METHYL 2,6-DICHLOROPYRIDINE-3-CARBOXYLA& is utilized as a versatile starting material in organic synthesis, enabling the production of a variety of organic compounds with different functional groups and applications. Its reactivity and stability make it a valuable component in the synthesis of complex organic molecules.
Used in Replacement of Halides:
METHYL 2,6-DICHLOROPYRIDINE-3-CARBOXYLA& is used in the replacement of chlorides with fluorides using anhydrous nucleophilic fluoride salts generated from potassium fluoride and an arene transfer agent. This process allows for the selective substitution of halide groups, enabling the synthesis of novel compounds with improved properties and applications.

InChI:InChI=1/C7H5Cl2NO2/c1-12-7(11)4-2-3-5(8)10-6(4)9/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 58584-83-1 2,6-dichloronicotinoyl chloride 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 77-78-1 dimethyl sulfate 
• 186581-53-3 diazomethane 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 65515-32-4 methyl 6-chloro-2-methoxypyridine-3-carboxylate 
• 65515-26-6 methyl 2,6-dimethoxypyridine-3-carboxylate 
• 95652-77-0 methyl 2-chloro-6-methoxypyridine-3-carboxylate 
• 237390-84-0 methyl 2-methoxy-6-(4-methylbenzenethio)pyridine-3-carboxylate 
• 275384-67-3 2-chloro-6-phenylpyridine-3-carboxylic acid methyl ester 
• 906794-87-4 methyl 2-chloro-6-(4-chlorophenoxy)nicotinate 
• 1005756-36-4 methyl 6-chloro-2-(3-fluorophenethylamino)nicotinate 
• 187480-13-3 methyl 2-methoxy-6-methylaminopyridine-3-carboxylate 
• 187480-17-7 5-bromo-2-methoxy-6-methylaminopyridine-3-carboxylic acid 
• 187480-15-5 methyl 5-bromo-2-methoxy-6-methylaminopyridine-3-carboxylate 
• 237390-81-7 methyl 2-methoxy-6-(4-methylbenzenesulfinyl)pyridine-3-carboxylate 
• 849805-25-0 methyl 2-amino-6-chloropyridine-3-carboxylate 
• 1246685-21-1 2-chloro-6-{3-chloro-4-[2-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzoimidazol-5-yl)-3,3,3-trifluoro-2-hydroxy-1-methyl-propyl]-phenoxy}-nicotinic acid methyl ester 
• 1246765-45-6 methyl 6-chloro-2-ethoxynicotinate 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE

Compounds of Formula I or pharmaceutically acceptable salts or esters thereof capable of binding to and modulating the activity of a stimulator of interferon genes (STING) protein are provided. Methods involving compounds of Formula I as effective modulators of STING are also provided.

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases

The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Following identification of a lead compound with a dihydronaphthalene central core by inducing conformational constraint, optimization of the lipophilic tail region led to the discovery of 13n as a clinical candidate that exhibited >30 000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing).